The most common grade 3/4 adverse events in the sorafenib and placebo arms were neutropenia ( 48 % vs. 22 % ) , peripheral neuropathy ( 16 % vs. 21 % ) , and grade 3 hand-foot skin reaction ( 20 % vs. 0 % ) .
